Jason Levin

Founder, Director and president

Jason has been with Orbus Therapeutics since it was established in 2012. Prior to founding
Orbus Therapeutics, Jason was Chief Business Officer of Sorbent Therapeutics, Inc., a
company focused on the development of oral polymers to treat chronic heart failure. Before
Sorbent, he was Chief Business Officer at Brain Cells, Inc., a CNS focused drug discovery and
development company. Previously, Jason was Vice President, Corporate Development and one
of the initial employees at Jazz Pharmaceuticals. He also held leadership roles at ALZA
Corporation, a wholly owned subsidiary of Johnson & Johnson. Jason received a BA from the
University of California, San Diego and a MBA from the University of Texas, McCombs
Graduate School of Business.

Jennifer Ekelund

HEAD, REGULATORY AFFAIRS AND QUALITY ASSURANCE

Jennifer joined Orbus Therapeutics in 2019 as its Head of Regulatory Affairs and Quality
Assurance. Prior to joining Orbus Therapeutics, she held the roles of Vice President of US
Regulatory Affairs and Vice President of Research and Development Quality Assurance and
Compliance at Jazz Pharmaceuticals between 2004-2018, focused on sleep, hematology, and
oncology. Before Jazz, Jennifer held positions of increasing responsibility in regulatory affairs
and compliance across multiple therapeutic areas and technologies at Alza Corporation, a
wholly owned subsidiary of Johnson & Johnson, from 1991-2004. Jennifer received a Bachelor
of Arts degree from Boston University.

Jackie Walling, MBChB, PhD

CHIEF MEDICAL OFFICER (CONSULTANT)

Jackie joined Orbus Therapeutics in 2022. Jackie is a seasoned pharmaceutical executive with
extensive experience in the global clinical development and research of anticancer drugs and
drugs for rare genetic diseases. Prior to her forming her own consulting company, Jackie held
senior positions across clinical development and research at Eli Lilly, Tularik, Axys
Pharmaceuticals and , BioMarin and prior to that practiced medicine in the UK. Jackie received
her medical degree from the University of Bristol and a PhD from the University of
Southampton.

Noymi Yam, PhD

VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER

Noymi joined Orbus Therapeutics in 2015 as Head of Product Development. Before Orbus, she
held senior roles across CMC, pharmaceutical/product development and research at
BiopharmX, Sorbent Therapeutics, Avantec Vascular and Alza Corporation (a Johnson &
Johnson company). Noymi received a master’s degree in chemical engineering from Riga
Technical University (Riga, Latvia) and a PhD in Pharmaceutical and Chemical Sciences from
the University of the Pacific (California). Noymi also serves as an adjunct Professor,
Department of Pharmaceutics and Medicinal Chemistry in the Thomas J. Long School of
Pharmacy at the University of the Pacific.